Moderate EvidencePromising research with growing clinical support from multiple studies
Acupuncture for Chronic Bronchitis
Chronic bronchitis is a clinical syndrome defined by a chronic productive cough for at least three months per year over two consecutive years, commonly occurring within the broader spectrum of chronic obstructive pulmonary disease (COPD). From a western medical perspective, airway inflammation, mucus hypersecretion, and impaired mucociliary clearance drive symptoms and exacerbate airflow limitation. Management focuses on symptom relief, prevention of exacerbations, preservation of lung function, and improvement of quality of life. Standard care includes smoking cessation, vaccinations, inhaled bronchodilators and corticosteroids for select patients, pulmonary rehabilitation, mucolytics in some cases, and targeted therapies such as roflumilast or long-term macrolides for exacerbation-prone phenotypes. Outcomes are typically tracked with lung function (FEV1), dyspnea scales (mMRC), quality-of-life tools (CAT, SGRQ), exercise tolerance (6-minute walk distance), and exacerbation frequency.
Where does acupuncture fit? Western clinical research on acupuncture for chronic bronchitis (often studied within COPD populations) has grown in the past two decades. Systematic reviews and randomized trials suggest acupuncture may modestly improve dyspnea, exercise capacity, and patient-reported quality of life when used alongside standard medical therapy. Some studies report better 6-minute walk distance, improvements in COPD assessment scores, and small gains in FEV1; others show minimal or no change in lung function but better symptom control. Proposed biomedical mechanisms include modulation of airway inflammation (e.g., influencing IL‑6, TNF‑α), autonomic balance (reduced vagal-mediated bronchoconstriction), improved ventilatory efficiency, and central effects on breathlessness perception. However, the evidence base has limitations: many trials are small, heterogeneous in technique and dosing, often conducted in single regions, and may have risk of bias. Sham-controlled designs
respiratory
Updated March 22, 2026